Business Description
Ipsen SA
ISIN : US4626292050
Share Class Description:
IPSEY: ADRTotal Employee Number:
5,535Compare
Compare
Traded in other countries / regions
IPN.France0MH6.UKIPSEY.USAI7G.GermanyIPN.AustriaIPNN.Mexico IPO Date
2007-08-14Description
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.76 | |||||
Equity-to-Asset | 0.63 | |||||
Debt-to-Equity | 0.2 | |||||
Debt-to-EBITDA | 0.7 | |||||
Interest Coverage | 21.33 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 4.42 | |||||
Beneish M-Score | -2.92 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.5 | |||||
3-Year EBITDA Growth Rate | 5 | |||||
3-Year EPS without NRI Growth Rate | -7.4 | |||||
3-Year FCF Growth Rate | 3.9 | |||||
3-Year Book Growth Rate | 9.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 3.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.75 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 89.28 | |||||
9-Day RSI | 73.23 | |||||
14-Day RSI | 63.68 | |||||
3-1 Month Momentum % | -7.21 | |||||
6-1 Month Momentum % | 31.12 | |||||
12-1 Month Momentum % | 50.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.96 | |||||
Quick Ratio | 1.79 | |||||
Cash Ratio | 1.06 | |||||
Days Inventory | 126.38 | |||||
Days Sales Outstanding | 69.08 | |||||
Days Payable | 414.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.96 | |||||
Dividend Payout Ratio | 0.14 | |||||
3-Year Dividend Growth Rate | 5.3 | |||||
Forward Dividend Yield % | 0.96 | |||||
5-Year Yield-on-Cost % | 1.32 | |||||
3-Year Average Share Buyback Ratio | 0.1 | |||||
Shareholder Yield % | -1.82 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 80.89 | |||||
Operating Margin % | 24.05 | |||||
Net Margin % | 11.29 | |||||
EBITDA Margin % | 31.77 | |||||
FCF Margin % | 20.63 | |||||
OCF Margin % | 28.99 | |||||
ROE % | 10.44 | |||||
ROA % | 6.58 | |||||
ROIC % | 15.55 | |||||
3-Year ROIIC % | -0.74 | |||||
ROC (Joel Greenblatt) % | 93.55 | |||||
ROCE % | 11.79 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 31.86 | |||||
Forward PE Ratio | 12.72 | |||||
PE Ratio without NRI | 17.67 | |||||
Shiller PE Ratio | 31.46 | |||||
Price-to-Owner-Earnings | 16.13 | |||||
PEG Ratio | 2.36 | |||||
PS Ratio | 3.6 | |||||
PB Ratio | 3.22 | |||||
Price-to-Tangible-Book | 9.88 | |||||
Price-to-Free-Cash-Flow | 17.45 | |||||
Price-to-Operating-Cash-Flow | 12.41 | |||||
EV-to-EBIT | 21.43 | |||||
EV-to-Forward-EBIT | 13.04 | |||||
EV-to-EBITDA | 10.7 | |||||
EV-to-Forward-EBITDA | 9 | |||||
EV-to-Revenue | 3.4 | |||||
EV-to-Forward-Revenue | 3.17 | |||||
EV-to-FCF | 16.49 | |||||
Price-to-GF-Value | 1.26 | |||||
Price-to-Projected-FCF | 1.23 | |||||
Price-to-DCF (Earnings Based) | 0.5 | |||||
Price-to-DCF (FCF Based) | 1.36 | |||||
Price-to-Median-PS-Value | 1.23 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.72 | |||||
Price-to-Graham-Number | 2.79 | |||||
| Price-to-Net-Current-Asset-Value | 62.51 | |||||
Earnings Yield (Greenblatt) % | 4.67 | |||||
FCF Yield % | 5.78 | |||||
Forward Rate of Return (Yacktman) % | 11.51 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:IPSEY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ipsen SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 4,566.926 | ||
| EPS (TTM) ($) | 1.539 | ||
| Beta | 0.0339 | ||
| 3-Year Sharpe Ratio | 0.57 | ||
| 3-Year Sortino Ratio | 0.96 | ||
| Volatility % | 24.17 | ||
| 14-Day RSI | 63.68 | ||
| 14-Day ATR ($) | 0.566887 | ||
| 20-Day SMA ($) | 46.2 | ||
| 12-1 Month Momentum % | 50.08 | ||
| 52-Week Range ($) | 30.05 - 51.1 | ||
| Shares Outstanding (Mil) | 330.56 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ipsen SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ipsen SA Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-07-31 13:00 | In 25 days | ||
| Second quarter earnings results for 2026 | 2026-07-31 07:00 | In 25 days | ||
| USD 0.461420 Cash Dividend | 2026-06-04 | 43.85 (+0.00%) | ||
| General meeting for 2026 | 2026-05-21 | 48.76 (+0.00%) | ||
| Annual report for 2025 | 2026-04-01 | 46.30 (+1.18%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-12 14:00 | 40.46 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-12 | 40.46 (+0.00%) | ||
| Second quarter earnings conference call for 2025 | 2025-07-31 13:00 | 32.22 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-07-31 07:00 | 32.22 (+0.00%) | ||
| USD 0.399055 Cash Dividend | 2025-06-09 | 30.32 (+0.23%) |
Show
Entries
Ipsen SA Frequently Asked Questions
What is Ipsen SA(IPSEY)'s stock price today?
The current price of IPSEY is $48.13. The 52 week high of IPSEY is $51.10 and 52 week low is $30.05.
When is next earnings date of Ipsen SA(IPSEY)?
The next earnings date of Ipsen SA(IPSEY) is 2026-07-31 Est..
Does Ipsen SA(IPSEY) pay dividends? If so, how much?
The Dividend Yield %  of Ipsen SA(IPSEY) is 0.96% (As of Today), Highest Dividend Payout Ratio of Ipsen SA(IPSEY) was 0.27. The lowest was 0.11. And the median was 0.14. The  Forward Dividend Yield % of Ipsen SA(IPSEY) is 0.96%. For more information regarding to dividend, please check our Dividend Page.
Guru Commentaries on OTCPK:IPSEY
No articles.
Press Release
Articles on Ipsen SA
No articles.
Headlines
See More- 1
Jul 01, 2026
Ipsen to acquire Memo Therapeutics in deal worth over €700M
Seeking Alpha • 12:24am
Jun 29, 2026
Ipsen to buy Kartos Therapeutics for $450M to boost oncology pipeline
Seeking Alpha • 4:10am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers